{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T16:46:49Z","timestamp":1772210809965,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.2146\/ajhp170707","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T10:30:22Z","timestamp":1527244222000},"page":"747-754","source":"Crossref","is-referenced-by-count":3,"title":["Proprotein convertase subtilisin\/kexin type 9 inhibitors for reduction of cardiovascular events"],"prefix":"10.1093","volume":"75","author":[{"given":"Ricky D.","family":"Turgeon","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen J.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of Alberta, Edmonton, Canada"},{"name":"Cardiac Transplant Clinic, Mazankowski Alberta Heart Institute, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041105255749100_b1-0750747","article-title":"The top 10 causes of death","author":"World Health Organization"},{"key":"key\n\t\t\t\t2019041105255749100_b2-0750747","first-page":"2889","article-title":"ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume-title":"J Am Coll Cardiol","author":"Stone","year":"2013"},{"key":"key\n\t\t\t\t2019041105255749100_b3-0750747","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","article-title":"Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"key\n\t\t\t\t2019041105255749100_b4-0750747","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b5-0750747","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1161\/CIRCULATIONAHA.115.016080","article-title":"Proprotein convertase subtilisin\/ kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk","volume":"132","author":"Bergeron","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105255749100_b6-0750747","volume-title":"Praluent (alirocumab) package insert","year":"2017"},{"key":"key\n\t\t\t\t2019041105255749100_b7-0750747","volume-title":"Repatha (evolocumab) package insert","year":"2016"},{"key":"key\n\t\t\t\t2019041105255749100_b8-0750747","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","article-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105255749100_b9-0750747","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105255749100_b10-0750747","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b11-0750747","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041105255749100_b12-0750747","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b13-0750747","first-page":"CD011748","article-title":"PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease","volume":"4","author":"Schmidt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019041105255749100_b14-0750747","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b15-0750747","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b16-0750747","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY Outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t2019041105255749100_b17-0750747","first-page":"14","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041105255749100_b18-0750747","article-title":"Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor","author":"Pfizer Inc","year":"2016"},{"key":"key\n\t\t\t\t2019041105255749100_b19-0750747","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","article-title":"Lipid-reduction variability and antidrug-antibody formation with bococizumab","volume":"376","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b20-0750747","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jamacardio.2017.0747","article-title":"Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia","volume":"2","author":"Koren","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t2019041105255749100_b21-0750747","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b22-0750747","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/CIRCULATIONAHA.116.025233","article-title":"Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies","volume":"135","author":"Toth","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105255749100_b23-0750747","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105255749100_b24-0750747","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jacc.2016.11.037","article-title":"Safety of very low low-density lipoprotein cholesterol levels with alirocumab","volume":"69","author":"Robinson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041105255749100_b25-0750747","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041105255749100_b26-0750747","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b27-0750747","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105255749100_b28-0750747","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041105255749100_b29-0750747","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105255749100_b30-0750747","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2016.14568","article-title":"Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes","volume":"316","author":"Lotta","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041105255749100_b31-0750747","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105255749100_b32-0750747","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key\n\t\t\t\t2019041105255749100_b33-0750747","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041105255749100_b34-0750747","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.2017.9924","article-title":"Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial","volume":"318","author":"Kazi","year":"2017","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041105255749100_b35-0750747","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol"},{"key":"key\n\t\t\t\t2019041105255749100_b36-0750747","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology task force on clinical expert consensus documents","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041105255749100_b37-0750747","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041105255749100_b38-0750747","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/CIRCULATIONAHA.117.028503","article-title":"Estimation of eligibility for PCSK9 inhibitors and associated costs based on the FOURIER trial: insights from the Department of Veterans Affairs","volume":"135","author":"Virani","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105255749100_b39-0750747","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/75\/11\/747\/28346328\/ajhp0747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T14:42:52Z","timestamp":1571409772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/75\/11\/747\/5101994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp170707","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,1]]},"published":{"date-parts":[[2018,6,1]]}}}